蔡耿彰(Tsai, Keng-Chang)

蔡耿彰實驗室生活照Current position:Associate Research Fellow
Education:Ph.D., Institute of Life Science, National Tsing Hua University
Telephone:+886-2-2820-1999 ext. 6241(Office)、6251(Lab)
E-mail : tkc@nricm.edu.tw

Major Professional Experiences:
Adjunct Associate Professor, Ph.D. Program for Biotechnology in Medicine, Taipei Medical University (2016/05~now)
Assistant Research Fellow, National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taiwan. (2013/07~2015/11)
Assistant Research Fellow, National Research Institute of Chinese Medicine, Taiwan. (2011/08~2013/07)
Postdoctoral Fellow, Genomics Research Center, Academia Sinica, Taiwan. (2005/10~2011/07)
Bio-Information Project Manager and Chinese-herb Database, Breadth Technology company (2004/02~2005/06)

Specialty:
 TCM Antibody Library, Phage Display Antibody/Peptide Library, Computer-aided Drug Design, Natural Product Database, Structural bio-informatics.

Research Description:
Our interest includes Four parts:
  1. To develop TCM antibody libraries for screening of targeted protein
  2. Finding receptor and ligand binding site with phage display peptide or antibody library platform to provide important 3D-QSAR and pharmacophore models which are employed to increase hits in screening active compounds/anti-compound antibodies.
  3. Affinity selection of Chinese herbal extracts and peptide phage library to obtain peptide sequence from which the most potential sequences are identified by experiment and computational molecular modeling and the target sequences are used to screen potential target protein for the disease diagnosis or analysis.3.
  4. Constructing a huge natural product database including Chinese Ancient Literatures, information of disease, protein targets, drug compounds, and natural-product compounds as well as pharmacophore models and docking strategy. 
Honor:  The 31th Symposium on Natural Products & Symposium on Pharmacy and Traditional Chinese Medicine (the first prize in TCM)
Chinese Publication:
  1. Chemical engineering and information, Vol.37, Application of Drug information in drug development.
  2. Wang-Chuan Chen*, Keng-Chang Tsai, Li-Wei Lin, Hui-Hsiung Lin, and  Chun-Chuan Shih.(2015) Investigation of Tyrosinase Inhibition by Chinese Herbal Medicine Small Molecules as Skin-whitening Ingredients, Taiwan Journal of Chinese Medicine. 13(1): 29-42.
  3. Li-Wei Lin, Yune-Fang Ueng, Keng-Chang Tsai, Hung-Ju Hsu, Chun-Chuan Shih, and Wang-Chuan Chen.* (2015) Investigation of Interaction between Shu-Gin-Hwai-Shen-tang and Anticoagulant Warfarin from the Perspective of Structural Biology, Taiwan Journal of Chinese Medicine. 13(1): 1-12.
    Published Papers:
Published Papers:
NCBI PubMed :  Keng-Chang Tsai (Please click!!) 
 Google Scholar :  Keng-Chang Tsai (Please click!!)
  1. Tseng TS, Lee CC, Chen PJ, Lin CY, Chen WC, Lee YC, Lin JH, Chen KW, Tsai KC*, Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering. J Chem Inf Model. 2024 Feb 14. doi: 10.1021/acs.jcim.3c01500. Online ahead of print.
  2. Lee WP, Tsai KC, Liao SX, Huang YH, Hou MC, Lan KH.  Ser235 phosphorylation of hepatitis C virus NS5A is required for NS5A dimerization and drug resistance. Life Sci. 2024 Jan 15;337:122338. doi: 10.1016/j.lfs.2023.122338. Epub 2023 Dec 10.
  3. Chang FL, Lee CC, Tsai KC, Lin TY, Chiang CW, Pan SL, Lee YC., An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. Biochem Biophys Res Commun. 2023 Dec 25;688:149214. doi: 10.1016/j.bbrc.2023.149214. Epub 2023
  4. Lee WP, Tsai KC, Liao SX, Huang YH, Hou MC, Lan KH., Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors. FEBS J. 2023 Dec 20. doi: 10.1111/febs.17039.
  5. Yu KH, Tien KW, Wang WC, Chi CH, Tsai KC, Chou CH, Hwang TL, Hung HY., Design and synthesis of pyrazole derivatives against neutrophilic inflammation. Eur J Med Chem. 2023 Dec 15;262:115874. doi: 10.1016/j.ejmech.2023.115874. Epub 2023 Oct 26.
  6. Yu KH, Kuo CY, Wu IT, Chi CH, Tsai KC, Kuo PC, Zeng JW, Hung CC*, Hung HY*. Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo. Eur J Pharmacol 2023:176146. https://doi.org:10.1016/j.ejphar.2023.176146
  7. Wei WC, Tsai KC(co-first), Liaw CC, Chiou CT, Tseng YH, Liao GY, Lin YC, Chiou WF, Liou KT, Yu IS, Shen YC*, Su YC*. NRICM101 ameliorates SARS-CoV-2-S1-induced pulmonary injury in K18-hACE2 mice model. Front Pharmacol 2023, 14:1125414. https://doi.org:10.3389/fphar.2023.1125414
  8. Wang HJ, Chen AC, Chen HY, Cheng HC, Kao LT, Lu CK, Tsai KC, Lee IJ, Ueng YF*. Identification of the perpetrator imperatorin in Xin-yi-san-theophylline interaction: observed and predicted herb-drug interaction in rats. J Pharm Pharmacol 2023, 75(9):1225-1236. https://doi.org:10.1093/jpp/rgad054
  9. Tseng HJ, Chen WC, Kuo TF, Yang G, Feng CS, Chen HM, Chen TY, Lee TH, Yang WC*, Tsai KC*, Huang WJ*. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice. Cell Mol Life Sci 2023, 80(4):101. https://doi.org:10.1007/s00018-022-04677-5
  10. Tsai KC, Chen CS, Su JH, Lee YC, Tseng YH, Wei WC*. The Blockade of Mitogen-Activated Protein Kinase 14 Activation by Marine Natural Product Crassolide Triggers ICD in Tumor Cells and Stimulates Anti-Tumor Immunity. Mar Drugs 2023, 21(4). https://doi.org:10.3390/md21040225
  11. Lee YC, Lai GH, Lin TY, Tseng TS, Tsai TH, Chen WC, Lee CC, Tsai KC*. Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testing. J Biol Eng 2023, 17(1):30. https://doi.org:10.1186/s13036-023-00350-y
  12. Chou O, Juang YP, Chao TL, Tsai SF, Chiu PF, Chiou CT, Tsai KC, Chang SY*, Liang PH*, Wong CH*. Isolation of Anti-SARS-CoV-2 Natural Products Extracted from Mentha canadensis and the Semi-synthesis of Antiviral Derivatives. J Nat Prod 2023, 86(6):1428-1436. https://doi.org:10.1021/acs.jnatprod.3c00104
  13. Chiu PF, Lin IC, Lu YL, Chang CN, Chan HY, Lin TS, Tsai KC, Hsieh YSY, Chen MJ, Lin MH*, Liang PH*. Design, structure-activity relationships, and enzyme kinetic studies of tricyclic and tetracyclic coumarin-based sulfamates as steroid sulfatase inhibitors. Bioorg Chem 2023, 138:106581. https://doi.org:10.1016/j.bioorg.2023.106581
  14. Chiang CW, Lin YS, Chang FL, Lin TY, Tsai KC, HuangFu WC*, Lee YC*. Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer. Biochem Biophys Res Commun 2023, 680:161-170. https://doi.org:10.1016/j.bbrc.2023.09.025
  15. Wei WC, Liaw CC, Tsai KC(co-first), Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC*, Su YC*. Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res 2022, 184:106424. https://doi.org:10.1016/j.phrs.2022.106424
  16. Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC*. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res 2022, 184:106412. https://doi.org:10.1016/j.phrs.2022.106412
  17. Tsai KC*, Zhang YX, Kao HY, Fung KM, Tseng TS*. Pharmacophore-driven identification of human glutaminyl cyclase inhibitors from foods, plants and herbs unveils the bioactive property and potential of Azaleatin in the treatment of Alzheimer's disease. Food Funct 2022, 13(24):12632-12647. https://doi.org:10.1039/d2fo02507h
  18. Lin YS, Hsieh SJ, Tsai KC, Cheng MH, Yang TW, Lin TY, Chang FL, Chiang CW, Chen WC, Huang HT*, Lee YC*. Blockade effect of avian-derived anti-VISTA antibodies on immunosuppressive responses. All Life 2022, 15(1):479-489. https://doi.org:10.1080/26895293.2022.2063951
  19. Chang CN, Lin IC, Lin TS, Chiu PF, Lu YL, Narwane M, Liu IC, Hng Y, Tsai KC, Lin MH, Y SYH, Chen MJ, Liang PH*. The Design, Structure-Activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-Tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as Steroid sulfatase inhibitors. Bioorg Chem 2022, 129:106148. https://doi.org:10.1016/j.bioorg.2022.106148
  20. Tung MC, Tsai KC(co-first), Fung KM, Don MJ, Tseng TS*. Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase. RSC Adv 2021, 11(4):2453-2461. https://doi.org:10.1039/d0ra08769f
  21. Tsai KC, Lee YC, Tseng TS*. Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. Front Microbiol 2021, 12:698365. https://doi.org:10.3389/fmicb.2021.698365
  22. Tsai KC, Huang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC*. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother 2021, 133:111037. https://doi.org:10.1016/j.biopha.2020.111037
  23. Lin TY, Tsai TH, Chen CT, Yang TW, Chang FL, Lo YN, Chung TS, Cheng MH, Chen WC, Tsai KC*, Lee YC*. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response. Exp Anim 2021, 70(3):333-343. https://doi.org:10.1538/expanim.20-0178
  24. Kuo TF, Hsu SW, Huang SH, Chang CL, Feng CS, Huang MG, Chen TY, Yang MT, Jiang ST, Wen TN, Yang CY, Huang CY, Kao SH, Tsai KC, Yang G, Yang WC*. Pdia4 regulates β-cell pathogenesis in diabetes: molecular mechanism and targeted therapy. EMBO Mol Med 2021, 13(10):e11668. https://doi.org:10.15252/emmm.201911668
  25. Chern CM, Lu CK, Liou KT, Wang YH, Tsai KC, Chang CL, Chang CC, Shen YC*. Medicarpin isolated from Radix Hedysari ameliorates brain injury in a murine model of cerebral ischemia. J Food Drug Anal 2021, 29(4):581-605. https://doi.org:10.38212/2224-6614.3377
  26. Lee YC, Huang HT, Chang CD, Chen CT, Lin TY, Yang TW, Chang FL, Lu MK, Chiou CT, Chen WC, Pan SL, Tsai KC*. Isolation of anti-VEGF monoclonal antibodies with neutralizing effects from an Astragalus-induced immune antibody library. Int Immunopharmacol 2020, 88:107007. https://doi.org:10.1016/j.intimp.2020.107007
  27. Hng Y, Lin MH, Lin TS, Liu IC, Lin IC, Lu YL, Chang CN, Chiu PF, Tsai KC, Chen MJ, Liang PH*. Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors. Bioorg Chem 2020, 96:103618. https://doi.org:10.1016/j.bioorg.2020.103618
  28. Chang FL, Tsai KC, Lin TY, Yang TW, Lo YN, Chen WC, Chang JH, Lu MK, Chiou CT, Chen PH, Yen Y*, Pan SL*, Lee YC*. Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. Biomed Res Int 2020, 2020:3415471. https://doi.org:10.1155/2020/3415471
  29. Tsai KC, Hung PP, Cheng CF, Chen C, Tseng TS*. Exploring the mode of action of inhibitors targeting the PhoP response regulator of Salmonella enterica through comprehensive pharmacophore approaches. RSC Adv 2019, 9(16):9308-9312. https://doi.org:10.1039/c9ra00620f
  30. Tsai KC, Chiang CW, Lo YN, Chang FL, Lin TY, Chang CY, Chen WC, Lee YC*. Generation and characterization of avian-derived anti-human CD19 single chain fragment antibodies. Anim Biotechnol 2019, 30(4):293-301. https://doi.org:10.1080/10495398.2018.1486323
  31. Tsai KC, Chang CD, Cheng MH, Lin TY, Lo YN, Yang TW, Chang FL, Chiang CW, Lee YC*, Yen Y*. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent. ACS Omega 2019, 4(1):2387-2397. https://doi.org:10.1021/acsomega.8b03072
  32. Wang YH, Liou KT, Tsai KC, Liu HK, Yang LM, Chern CM, Shen YC*. GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice. Toxicol Appl Pharmacol 2018, 357:88-105. https://doi.org:10.1016/j.taap.2018.08.023
  33. Wang PC, Chiu DC, Jan JT, Huang WI, Tseng YC, Li TT, Cheng TJ, Tsai KC, Fang JM*. Peramivir conjugates as orally available agents against influenza H275Y mutant. Eur J Med Chem 2018, 145:224-234. https://doi.org:10.1016/j.ejmech.2017.12.072
  34. Tseng TS, Tu IF, Chen HT, Lin LC, Tsai KC*, Wu SH*, Chen C*. Protein-DNA complex-guided discovery of the antibacterial lead E1 for restoring the susceptibility of Klebsiella Pneumoniae to polymyxin B by targeting the response regulator PmrA. Chem Commun (Camb) 2018, 54(49):6372-6375. https://doi.org:10.1039/c8cc01840e
  35. Kuo LY, Tseng PY, Lin YC, Liaw CC, Zhang LJ, Tsai KC, Lin ZH, Ho HO, Kuo YH*. New Hirsutinolide-Type Sesquiterpenoids from Vernonia cinerea Inhibit Nitric Oxide Production in LPS-Stimulated RAW264.7 Cells. Planta Med 2018, 84(18):1348-1354. https://doi.org:10.1055/a-0647-1901
  36. Hsu PH, Chiu DC, Wu KL, Lee PS, Jan JT, Cheng YE, Tsai KC, Cheng TJ, Fang JM*. Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. Eur J Med Chem 2018, 154:314-323. https://doi.org:10.1016/j.ejmech.2018.05.030
  37. Chang CY, Chang FL, Chiang CW, Lo YN, Lin TY, Chen WC, Tsai KC, Lee YC*. Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope. Viral Immunol 2018, 31(7):492-499. https://doi.org:10.1089/vim.2017.0200
  38. Tseng TS, Tsai KC, Chen C*. Characterizing the structure-function relationship reveals the mode of action of a novel antimicrobial peptide, P1, from jumper ant Myrmecia pilosula. Mol Biosyst 2017, 13(6):1193-1201. https://doi.org:10.1039/c6mb00810k
  39. Kuo TF, Chen TY, Jiang ST, Chen KW, Chiang YM, Hsu YJ, Liu YJ, Chen HM, Yokoyama KK, Tsai KC, Yeh HH, Chen YR, Yang MT, Yang CY, Yang WC*. Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway. Oncogene 2017, 36(39):5484-5496. https://doi.org:10.1038/onc.2017.156
  40. Chiu DC, Lin TC, Huang WI, Cheng TJ, Tsai KC, Fang JM*. Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus. Org Biomol Chem 2017, 15(46):9910-9922. https://doi.org:10.1039/c7ob02374j
  41. Wang PC, Fang JM*, Tsai KC, Wang SY, Huang WI, Tseng YC, Cheng YS, Cheng TJ, Wong CH. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. J Med Chem 2016, 59(11):5297-5310. https://doi.org:10.1021/acs.jmedchem.6b00029
  42. Tseng TS, Wang SH, Chang TW, Wei HM, Wang YJ, Tsai KC, Liao YD, Chen C*. Sarkosyl-Induced Helical Structure of an Antimicrobial Peptide GW-Q6 Plays an Essential Role in the Binding of Surface Receptor OprI in Pseudomonas aeruginosa. PLoS One 2016, 11(10):e0164597. https://doi.org:10.1371/journal.pone.0164597
  43. Tseng TS, Lee YC, Hsiao NW, Liu YR, Tsai KC*. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors. Bioorg Med Chem Lett 2016, 26(2):265-271. https://doi.org:10.1016/j.bmcl.2015.12.043
  44. Tseng TS, Chuang SM, Hsiao NW, Chen YW, Lee YC, Lin CC, Huang C, Tsai KC*. Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. Mol Biosyst 2016, 12(8):2541-2551. https://doi.org:10.1039/c6mb00229c
  45. Tsay HJ, Huang YC, Chen YJ, Lee YH, Hsu SM, Tsai KC, Yang CN, Huang FL, Shie FS, Lee LC, Shiao YJ*. Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO. J Biomed Sci 2016, 23:27. https://doi.org:10.1186/s12929-016-0244-5
  46. Jian JW, Elumalai P, Pitti T, Wu CY, Tsai KC, Chang JY, Peng HP, Yang AS*. Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms. PLoS One 2016, 11(8):e0160315. https://doi.org:10.1371/journal.pone.0160315
  47. Tseng TS, Tsai KC(co-first), Chen WC, Wang YT, Lee YC, Lu CK, Don MJ, Chang CY, Lee CH, Lin HH, Hsu HJ, Hsiao NW*. Discovery of Potent Cysteine-Containing Dipeptide Inhibitors against Tyrosinase: A Comprehensive Investigation of 20 × 20 Dipeptides in Inhibiting Dopachrome Formation. J Agric Food Chem 2015, 63(27):6181-6188. https://doi.org:10.1021/acs.jafc.5b01026
  48. Lo SN, Shen CC, Chang CY, Tsai KC, Huang CC, Wu TS, Ueng YF*. The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition. Drug Metab Dispos 2015, 43(7):1100-1107. https://doi.org:10.1124/dmd.115.063966
  49. Li A, Yang D, Zhu M, Tsai KC, Xiao KH, Yu X, Sun J, Du L*. Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics. Future Med Chem 2015, 7(18):2429-2437. https://doi.org:10.4155/fmc.15.160
  50. Lee YC, Hsiao NW, Tseng TS, Chen WC, Lin HH, Leu SJ, Yang EW, Tsai KC*. Phage display-mediated discovery of novel tyrosinase-targeting tetrapeptide inhibitors reveals the significance of N-terminal preference of cysteine residues and their functional sulfur atom. Mol Pharmacol 2015, 87(2):218-230. https://doi.org:10.1124/mol.114.094185
  51. Lee YC, Chen WC, Liang MH, Lee CH, Tsai KC, Chiang JR, Chiang LC, Chen CC, Chang CY, Lee CH, Leu SJ, Yang YY*. Single chain antibody fragment with serine protease inhibitory property capable of neutralizing toxicity of Trimeresurus mucrosquamatus venom. Biochem Biophys Res Commun 2015, 460(2):170-176. https://doi.org:10.1016/j.bbrc.2015.02.169
  52. Ho CW, Van Meervelt V, Tsai KC, De Temmerman PJ, Mast J, Maglia G*. Engineering a nanopore with co-chaperonin function. Sci Adv 2015, 1(11):e1500905. https://doi.org:10.1126/sciadv.1500905
  53. Chen WC, Tseng TS, Hsiao NW, Lin YL, Wen ZH, Tsai CC, Lee YC, Lin HH, Tsai KC*. Discovery of highly potent tyrosinase inhibitor, T1, with significant anti-melanogenesis ability by zebrafish in vivo assay and computational molecular modeling. Sci Rep 2015, 5:7995. https://doi.org:10.1038/srep07995
  54. Chang YP, Huang CC, Shen CC, Tsai KC, Ueng YF*. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet 2015, 30(5):374-383. https://doi.org:10.1016/j.dmpk.2015.08.006
  55. Hsiao NW, Tseng TS, Lee YC, Chen WC, Lin HH, Chen YR, Wang YT, Hsu HJ, Tsai KC*. Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors. J Chem Inf Model 2014, 54(11):3099-3111. https://doi.org:10.1021/ci500370x
  56. Hong BT, Chen CL, Fang JM*, Tsai KC, Wang SY, Huang WI, Cheng YE, Wong CH. Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors. Bioorg Med Chem 2014, 22(23):6647-6654. https://doi.org:10.1016/j.bmc.2014.10.005
  57. Chen CY, Huang CC, Tsai KC, Huang WJ, Huang WC, Hsu YC, Hsu FL*. Evaluation of the Antihyperuricemic Activity of Phytochemicals from Davallia formosana by Enzyme Assay and Hyperuricemic Mice Model. Evid Based Complement Alternat Med 2014, 2014:873607. https://doi.org:10.1155/2014/873607
  58. Chen CL, Lin TC, Wang SY, Shie JJ, Tsai KC, Cheng YS, Jan JT, Lin CJ*, Fang JM*, Wong CH*. Tamiphosphor monoesters as effective anti-influenza agents. Eur J Med Chem 2014, 81:106-118. https://doi.org:10.1016/j.ejmech.2014.04.082
  59. Lo SN, Chang YP, Tsai KC, Chang CY, Wu TS, Ueng YF*. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol Appl Pharmacol 2013, 272(3):671-680. https://doi.org:10.1016/j.taap.2013.07.005
  60. Lee YC, Tsai KC, Leu SJ, Wang TJ, Liu CY, Yang YY*. Isolation, characterization, and molecular modeling of a rheumatoid factor from a Hepatitis C virus infected patient with Sjögren's syndrome. ScientificWorldJournal 2013, 2013:516516. https://doi.org:10.1155/2013/516516
  61. Yu CM, Peng HP, Chen IC, Lee YC, Chen JB, Tsai KC, Chen CT, Chang JY, Yang EW, Hsu PC, Jian JW, Hsu HJ, Chang HJ, Hsu WL, Huang KF, Ma AC, Yang AS*. Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. PLoS One 2012, 7(3):e33340. https://doi.org:10.1371/journal.pone.0033340
  62. Tsai KC, Jian JW, Yang EW, Hsu PC, Peng HP, Chen CT, Chen JB, Chang JY, Hsu WL, Yang AS*. Prediction of carbohydrate binding sites on protein surfaces with 3-dimensional probability density distributions of interacting atoms. PLoS One 2012, 7(7):e40846. https://doi.org:10.1371/journal.pone.0040846
  63. Chen HJ, Shen YC, Lin CY, Tsai KC, Lu CK, Shen CC, Lin YL*. Metabolomics study of Buyang Huanwu Tang Decoction in ischemic stroke mice by 1H NMR. Metabolomics 2012, 8(5):974-984. https://doi.org:10.1007/s11306-011-0394-0
  64. Chen CT, Peng HP, Jian JW, Tsai KC, Chang JY, Yang EW, Chen JB, Ho SY, Hsu WL, Yang AS*. Protein-protein interaction site predictions with three-dimensional probability distributions of interacting atoms on protein surfaces. PLoS One 2012, 7(6):e37706. https://doi.org:10.1371/journal.pone.0037706
  65. Zhang L, Tsai KC, Du L, Fang H, Li M, Xu W*. How to generate reliable and predictive CoMFA models. Curr Med Chem 2011, 18(6):923-930. https://doi.org:10.2174/092986711794927702
  66. Yang FL, Yang YL, Liao PC, Chou JC, Tsai KC, Yang AS, Sheu F, Lin TL, Hsieh PF, Wang JT, Hua KF, Wu SH*. Structure and immunological characterization of the capsular polysaccharide of a pyrogenic liver abscess caused by Klebsiella pneumoniae: activation of macrophages through Toll-like receptor 4. J Biol Chem 2011, 286(24):21041-21051. https://doi.org:10.1074/jbc.M111.222091
  67. Shie JJ, Fang JM*, Lai PT, Wen WH, Wang SY, Cheng YS, Tsai KC, Yang AS, Wong CH. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. J Am Chem Soc 2011, 133(44):17959-17965. https://doi.org:10.1021/ja207892q
  68. Wen WH, Wang SY, Tsai KC, Cheng YS, Yang AS, Fang JM*, Wong CH. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 2010, 18(11):4074-4084. https://doi.org:10.1016/j.bmc.2010.04.010
  69. Tsai KC, Chen YC, Hsiao NW, Wang CL, Lin CL, Lee YC, Li M*, Wang B*. A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. Eur J Med Chem 2010, 45(4):1544-1551. https://doi.org:10.1016/j.ejmech.2009.12.063
  70. Ho CW, Popat SD, Liu TW, Tsai KC, Ho MJ, Chen WH, Yang AS, Lin CH*. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors. ACS Chem Biol 2010, 5(5):489-497. https://doi.org:10.1021/cb100011u
  71. Yang Q, Du L, Tsai KC, Wang X, Li M*, You Q. Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR & Combinatorial Science 2009, 28(1):59-71. https://doi.org:https://doi.org/10.1002/qsar.200810050
  72. Wang SY, Tseng CP, Tsai KC, Lin CF, Wen CY, Tsay HS, Sakamoto N, Tseng CH, Cheng JC*. Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq. Biochem Biophys Res Commun 2009, 385(2):230-235. https://doi.org:10.1016/j.bbrc.2009.05.043
  73. Tsai KC, Teng LW, Shao YM, Chen YC, Lee YC, Li M, Hsiao NW*. The first pharmacophore model for potent NF-kappaB inhibitors. Bioorg Med Chem Lett 2009, 19(19):5665-5669. https://doi.org:10.1016/j.bmcl.2009.08.021
  74. Tsai KC, Wang SH, Hsiao NW, Li M*, Wang B*. The effect of different electrostatic potentials on docking accuracy: a case study using DOCK5.4. Bioorg Med Chem Lett 2008, 18(12):3509-3512. https://doi.org:10.1016/j.bmcl.2008.05.026
  75. Shao YM, Yang WB, Kuo TH, Tsai KC, Lin CH, Yang AS, Liang PH, Wong CH*. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg Med Chem 2008, 16(8):4652-4660. https://doi.org:10.1016/j.bmc.2008.02.040
  76. Lu IL, Tsai KC, Chiang YK, Jiaang WT, Wu SH, Mahindroo N, Chien CH, Lee SJ, Chen X, Chao YS, Wu SY*. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2008, 43(8):1603-1611. https://doi.org:10.1016/j.ejmech.2007.11.014
  77. Hsu HJ, Tsai KC, Sun YK, Chang HJ, Huang YJ, Yu HM, Lin CH, Mao SS, Yang AS*. Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. J Biol Chem 2008, 283(18):12343-12353. https://doi.org:10.1074/jbc.M708843200
  78. Shie JJ, Fang JM*, Wang SY, Tsai KC, Cheng YS, Yang AS, Hsiao SC, Su CY, Wong CH. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007, 129(39):11892-11893. https://doi.org:10.1021/ja073992i
  79. Shao YM, Yang WB, Peng HP, Hsu MF, Tsai KC, Kuo TH, Wang AH, Liang PH, Lin CH, Yang AS*, Wong CH*. Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. Chembiochem 2007, 8(14):1654-1657. https://doi.org:10.1002/cbic.200700254
  80. Tsai KC, Chen SY, Liang PH, Lu IL, Mahindroo N, Hsieh HP, Chao YS, Liu L, Liu D, Lien W, Lin TH*, Wu SY*. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006, 49(12):3485-3495. https://doi.org:10.1021/jm050852f
  81. Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY*. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem 2006, 49(17):5154-5161. https://doi.org:10.1021/jm060207o
  82. Lin TH*, Chiu SH, Tsai KC. Supervised feature ranking using a genetic algorithm optimized artificial neural network. J Chem Inf Model 2006, 46(4):1604-1614. https://doi.org:10.1021/ci0600354
  83. Zheng ZL, Zuo ZY, Liu ZG, Tsai KC, Liu AF, Zou GL*. Construction of a 3D model of nattokinase, a novel fibrinolytic enzyme from Bacillus natto. A novel nucleophilic catalytic mechanism for nattokinase. J Mol Graph Model 2005, 23(4):373-380. https://doi.org:10.1016/j.jmgm.2004.10.002
  84. Wei HY, Tsai KC, Lin TH*. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. J Chem Inf Model 2005, 45(5):1343-1351. https://doi.org:10.1021/ci050140y
  85. Li MY, Tsai KC, Xia L*. Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett 2005, 15(3):657-664. https://doi.org:10.1016/j.bmcl.2004.11.032
  86. Du LP, Li MY, Tsai KC, You QD, Xia L*. Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochem Biophys Res Commun 2005, 332(3):677-687. https://doi.org:10.1016/j.bbrc.2005.04.165
  87. Tsai KC, Lin TH*. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques. J Chem Inf Comput Sci 2004, 44(5):1857-1871. https://doi.org:10.1021/ci049824g
  88. Liu HC, Lyu PC, Leong MK, Tsai KC, Hsiue GH*. 3D-QSAR studies on PU3 analogues by comparative molecular field analysis. Bioorg Med Chem Lett 2004, 14(3):731-734. https://doi.org:10.1016/j.bmcl.2003.11.024
  89. Lin TH*, Li HT, Tsai KC. Implementing the Fisher's discriminant ratio in a k-means clustering algorithm for feature selection and data set trimming. J Chem Inf Comput Sci 2004, 44(1):76-87. https://doi.org:10.1021/ci030295a
  90. Du LP, Tsai KC, Li MY, You QD, Xia L*. The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett 2004, 14(18):4771-4777. https://doi.org:10.1016/j.bmcl.2004.06.070
  91. Lin TH*, Tsai KC, Lo TC. Homology modeling of the central catalytic domain of insertion sequence ISLC3 isolated from Lactobacillus casei ATCC 393. Protein Eng 2003, 16(11):819-829. https://doi.org:10.1093/protein/gzg107